Verve Therapeutics (NASDAQ:VERV) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.69) by 14.49 percent. This is a 18.06 percent increase over losses of $(0.72) per share from the same period last year. The company reported quarterly sales of $6.87 million which beat the analyst consensus estimate of $2.81 million by 144.31 percent. This is a 120.24 percent increase over sales of $3.12 million the same period last year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。